Mycobacterium tuberculosis: New tricks for an old bug

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 4, 2004, Pages 467-469

  Spigelman, Melvin ^a   Ma, Zhenkun ^b  

^a Global Alliance for TB Drug Devmt ^*  (United States)

^b Cumbre Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BIOFILM; DRUG RESEARCH; EDITORIAL; ERADICATION THERAPY; GROWTH RATE; HUMAN; HYPOTHESIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; TREATMENT PLANNING; TUBERCULOSIS;

EID: 4444348772     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.4.467     Document Type: Editorial

References (7)

1. Young DB. Strategies for new drug development. In: Tuberculosis, Pathogenesis, Protection and Control. Bloom BR (Ed.), ASM Press, Washington DC, USA (1994).
2. Hengge-Aronis R. Survival of hunger and stress: the role of rpoS in early stationary phase gene regulation in E. coli. Cell 72, 165-168 (1993).
3. Ma Z Morris TW, Combrink KD. Therapeutic opportunities for the treatment of biofilm-associated infections. Ann. Rep. Med. Chem. (2004) (In press).
4. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999).
5. Williams I, Venables WA, Loyd D et al. The effects of adherence to silicone surface on antibiotic susceptibility in Staphylococcus aureus. Microbiology 143, 2407-2413 (1997).
6. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J. Clin. Invest. 112, 1300-1307 (2003).
7. Norton L, Simon R. Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat. Rep. 61, 1307-1317 (1977).